Get started
Work

Dupilumab Efficacy in Children With Uncontrolled, Moderate-to-Severe, Type 2 Asthma by Allergen Sensitization Level

Year: 2026
Type: article
Abstract: BACKGROUND: Children with uncontrolled, moderate-to-severe asthma often have type 2 disease with allergic sensitization and/or elevated serum IgE. OBJECTIVE: To examine dupilumab efficacy in children aged 6 to 11 years with/without allergen sensitization. METHODS: ), Interviewer-Administered 7-Item Asthma Control Questionnaire (ACQ-7-IA) score, and total and allergen-specific IgE levels. RESULTS: , ACQ-7-IA, and total IgE levels. CONCLUSION: In children with type 2 asthma, dupilumab showed significant efficacy, reducing exacerbations and improving other outcomes in monoallergen- and multiallergen-sensitized patients, and numerical but nonsignificant effects in nonsensitized patients.
DOI: 10.1016/j.jaip.2026.06.012
Authors: Wanda Phipatanakul, Nikolaos G. Papadopoulos, Vivian Hernandez-Trujillo, Eckard Hamelmann, Robert S. Zeiger, Francine M. Ducharme, Changming Xia, Rebecca Gall, Olivier Ledanois, Amr Radwan, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz
Institutions: Boston Children's Hospital, Harvard University, National and Kapodistrian University of Athens, University of Manchester, Bielefeld University, Kaiser Permanente Bernard J. Tyson School of Medicine, Université de Montréal, Regeneron (United States), Sanofi (France)
Language: English
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $4,000
OpenAlex ID: W7165144719
FWCI:
Cites: 19
Cited by:
Related to: 10